Multiprofile Hospital For Active Treatment - Targovishte AD
- Address
- lock Available on a paid plan
Psychiatry and Psychology
At Multiprofile Hospital For Active Treatment - Targovishte AD, clinical research in Psychiatry and Psychology focuses on major depressive disorder and schizophrenia. The studies are aimed at evaluating new treatment options, assessing long-term safety, and understanding how therapies may improve symptoms and daily functioning.
- Research on major depressive disorder is exploring ways to improve depression relief and support better treatment response.
- Several trials examine schizophrenia in both adolescents and adults, with attention to symptom control and overall safety.
- Some studies also look at cognitive and behavioral symptoms linked to schizophrenia, helping clarify treatment benefits beyond core psychotic symptoms.
The psychiatry team at this hospital contributes to studies that may help refine care for people living with complex mental health conditions.
Nervous System Diseases
Clinical trials in the area of Nervous System Diseases at the Psychiatry Department in Targovishte include research on schizophrenia and related cognitive disorder. These studies are designed to test new therapies and better understand their impact on cognition, behavior, and overall psychiatric stability.
- Studies in schizophrenia are evaluating potential treatments for adults who need inpatient care as well as younger patients.
- Research into cognitive disorder and cognitive impairment associated with schizophrenia aims to improve thinking and memory-related outcomes.
- Ongoing work also includes assessment of treatment effectiveness and long-term tolerability in people with serious brain-related conditions.
This line of research reflects a broader effort to improve both symptom management and quality of life for patients affected by neurological and psychiatric disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Gedeon Richter Plc.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multiprofile Hospital For Active Treatment - Targovishte AD
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NBI-1117570 in Hospitalized Adults with Schizophrenia | Neurocrine Biosciences Inc. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine | 2 | Unknown | 2024-07-18 | 2024-09-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.